Bayer is taking multiple shots at Parkinson’s disease with BlueRock dosing its first patient in a Phase I stem cell study, and AskBio is assessing a gene therapy treatment for the disease.

The tool developed by On Target boosts the ability of surgeons to find and remove cancerous lesions during surgical procedures, increasing progression free and overall survival.

Unicorn Hunters is a new Internet reality show where startup companies can pitch a group of well-known panelists dubbed the “Circle of Money” which allows for a kind of crowdsourced funding appeal.

Not everyone is so confident that Aduhelm will transform the Alzheimer’s drug development landscape.

Please check out the biopharma industry's COVID-19 stories that are trending for June 8, 2021.

The findings also highlight additional mechanistic, drug product stability, pharmacokinetics and toxicology studies that support the candidate as a potential HIV prevention and treatment.

Indivior PLC is collaborating with France-based Aelis Farma on the development of a treatment for cannabis use disorder and cannabis-induced psychosis.

As a result of the termination, argenx will regain worldwide rights to cusatuzumab, its anti-CD70 antibody, from Cilag FmbH International, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

BioSpace recently interviewed Elizabeth Elting, founder and CEO of the Elizabeth Elting Foundation, to discuss her thoughts on how the pandemic has affected women in the workforce.

It's important to understand that as someone in the meeting, there are things you can do personally to become a more effective contributor. Here are four tips for being more productive in meetings.

New research identified a novel interaction between the SARS-CoV-2 spike protein and the galectin-3-binding protein (LGALS3BP) which could be a new therapeutic anti-viral target. The research also found the presence of detectable viral RNA in blood in COVID-19 patients is a strong predictor of mortality.

An experimental, lab-made antibody can completely prevent nonhuman primates from being infected with the monkey form of HIV, new research published in Nature Communications shows.

The results will inform a future human clinical trial evaluating leronlimab as a potential pre-exposure prophylaxis, or PrEP, therapy to prevent human infection from the virus that causes AIDS.

The U.S. Food and Drug Administration granted approval of Biogen’s aducanumab for the treatment of Alzheimer’s disease.

Wegovy is the first and only once-weekly GLP-1 receptor agonist that’s been approved for weight control in people living with obesity. This is the same drug used to treat type 2 diabetes.

Grail presents its first data from the interventional PATHFINDER trial of Galleri, its multi-cancer early detection blood test. Galleri is now available in the U.S. by prescription.

After three years, 85.9% of patients treated post-surgically with Lynparza were free of invasive breast cancer and second cancers compared to 77.1% of the placebo group.

In the field of drug discovery, one must always begin with the target, right? Not if you ask Cellarity, a quickly emerging biotech company revolutionizing the drug development space.

June is turning out to be a busy month for PDUFA dates for the U.S. Food and Drug Administration. Here’s a look at this week’s dates.

United claims Liquidia and a former employee misappropriated its trade secrets such as regulatory submissions and detailed financial forecasts for its inhaled treprostinil.

The FDA lifted the clinical holds on bluebird bio’s sickle gene therapy and its betibeglogene autotemcel gene therapy for adults, adolescents and children with TDT.